Spots Global Cancer Trial Database for cnto 328
Every month we try and update this database with for cnto 328 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT01266811 | Multiple Myelom... | Placebo, Velcad... Siltuximab, Vel... | 18 Years - | Centocor, Inc. | |
| S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00433446 | Prostate Cancer | CNTO 328 | 18 Years - | SWOG Cancer Research Network | |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | NCT01024036 | Multicentric Ca... | Siltuximab Placebo Best Supportive... | 18 Years - | Janssen Research & Development, LLC | |
| A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma | NCT01219010 | Monoclonal Gamm... Multiple Myelom... Plasma Cell Neo... | Siltuximab | 18 Years - | Janssen Research & Development, LLC | |
| A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma | NCT01309412 | Multiple Myelom... | Siltuximab | 20 Years - | Janssen Pharmaceutical K.K. | |
| A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00401765 | Prostatic Neopl... | CNTO 328 Docetaxel | 18 Years - | Centocor, Inc. | |
| A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors | NCT00841191 | Ovarian Neoplas... Pancreatic Neop... Colorectal Neop... Head and Neck N... Lung Neoplasms | CNTO 328; Anti-... CNTO 328; Anti-... CNTO 328; Anti-... CNTO 328; Anti-... CNTO 328; Anti-... CNTO 328; Anti-... CNTO 328; Anti-... | 18 Years - | Centocor, Inc. | |
| S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00433446 | Prostate Cancer | CNTO 328 | 18 Years - | SWOG Cancer Research Network | |
| An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | NCT00402181 | Multiple Myelom... | Siltuximab Dexamethasone | 18 Years - | Centocor, Inc. | |
| An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | NCT00402181 | Multiple Myelom... | Siltuximab Dexamethasone | 18 Years - | Centocor, Inc. | |
| A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease | NCT00412321 | Lymphoma, Non-H... Multiple Myelom... Giant Lymph Nod... | CNTO 328 | 18 Years - | Centocor, Inc. | |
| Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | NCT01531998 | Myeloma | Lenalidomide Bortezomib Siltuximab Dexamethasone Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | NCT01024036 | Multicentric Ca... | Siltuximab Placebo Best Supportive... | 18 Years - | Janssen Research & Development, LLC | |
| S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer | NCT00311545 | Kidney Cancer | CNTO 328 | 18 Years - | SWOG Cancer Research Network |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
